Entity

Time filter

Source Type

Wingate, NC, United States

Wingate University is a private comprehensive university with nearly 2,700 students on three campuses in Wingate, Charlotte and Hendersonville, in North Carolina, United States. It was founded by Baptists in 1896 as Wingate School, an independent, co-educational institution and became a four-year college in 1977. In 1996, Wingate College became Wingate University.The university offers 34 undergraduate majors, 37 minors and career concentrations, numerous pre-professional programs, graduate degrees in business, accounting, education, physician assistant studies and sport administration, and doctorates in pharmacy, physical therapy and education.Wingate University is listed sixth among Best Value colleges and universities in the South based on quality and net cost according to the recently released ranking of the nation's top schools in U.S. News & World Report's 2012 Best Colleges. Wingate student athletes compete in 22 NCAA Division II sports, and the University has won the South Atlantic Conference Echols Athletic Excellence Award for the past seven years. Wingate University's main campus is located in Union County, North Carolina on a 400-acre campus 30 miles east of Charlotte. A high percentage of students live on campus all four years. Wikipedia.


Koliscak L.,Wingate University
American Journal of Health-System Pharmacy | Year: 2012

Purpose. Published evidence on the incidence and predictors of venous thromboembolism (VTE) in patients with cirrhosis of the liver is reviewed. Summary. The frequently observed phenomenon of elevated International Normalized Ratio (INR) values in patients with cirrhosis has led to a theory of "autoanticoagulation" and the assertion that such patients may not benefit from the VTE risk-reduction therapies routinely used in other groups of hospitalized patients. A literature search identified six reports specifically addressing the issue of VTE risk in patients with cirrhosis. Reported rates of VTE development in such patients vary widely (0.5-8.2%) as a result of investigators' use of varying study methods and endpoints. The results of three studies (including two studies of longitudinal data on about 100,000 and nearly 450,000 patients) found no significant correlation of INR values and VTE risk. With regard to potential clinical markers of VTE risk in the context of cirrhosis, data from two studies suggested that serum albumin might serve as a reliable marker of coagulation status and, therefore, VTE risk. The results of other studies indicated that independent predictors of VTE in patients with cirrhosis include malnutrition and significant comorbidities such as chronic kidney disease and congestive heart failure. In aggregate, the available evidence does not support the autoanticoagulation theory. Conclusion. In hospitalized patients with cirrhosis who have elevated INR values, pharmacologic VTE prophylaxis should be strongly considered if there is no active or recent bleeding and if more than one risk factor for VTE is present. Copyright © 2012, American Society of Health-System Pharmacists, Inc. All rights reserved. Source


Dirks-Naylor A.J.,Wingate University | Lennon-Edwards S.,University of Delaware
Journal of Steroid Biochemistry and Molecular Biology | Year: 2011

It is thought that every cell in the body expresses the vitamin D receptor, and therefore vitamin D may play a role in health and homeostasis of every organ system, including skeletal muscle. Human, animal, and cell culture studies have collectively shown that vitamin D affects muscle strength and function. Vitamin D functions in a plethora of cellular processes in skeletal muscle including calcium homeostasis, cell proliferation, cell differentiation, fiber size, prevention of fatty degeneration, protection against insulin resistance and arachidonic acid mobilization. These processes appear to be mediated by several signaling pathways affected by vitamin D. This review aims to explore the effects of vitamin D on skeletal muscle in each model system and to delineate potential cell signaling pathways affected by vitamin D. © 2011 Elsevier Ltd. All rights reserved. Source


Amabile C.M.,Wingate University | Vasudevan A.,Carolinas Medical Center
Pharmacotherapy | Year: 2013

Epilepsy is defined as a tendency toward recurrent seizures unprovoked by any systemic or acute neurologic insults. It is a disruption of the electrical conductivity or activity in the brain, resulting in a seizure. In the United States, approximately 120 of every 100,000 people seek medical attention due to new seizure activity. Ezogabine, known as retigabine in Europe, is an ethyl N-(2- amino-4-[{fluorophenyl}methlamino]phenylcarbamate). The drug has been approved by the United States Food and Drug Administration (FDA) and European Medicines Agency for adjunctive treatment of partial-onset seizures in adults. Ezogabine exerts its therapeutic effect by enhancing transmembrane potassium channels (KCNQ ion channels), which is a novel mechanism in comparison with other antiepileptics. There are no specific documented contraindications to ezogabine. Warnings target patients that have benign prostatic hyperplasia or are receiving concomitant anticholinergic drugs due to a risk of urinary retention (2%). The FDA has required that ezogabine be part of a risk evaluation and mitigation strategy program in order to inform health care professionals of the risk of urinary retention. Prescribers should inform patients that ezogabine can cause urinary retention, including urinary hesitation, and instruct them to seek immediate medical attention if these symptoms occur. A medication guide has been developed for distribution to patients. Source


Meade L.T.,Wingate University
Diabetes Technology and Therapeutics | Year: 2012

Since the late 1970s, self-monitoring of blood glucose has been the standard for assessing daily glycemic control. The first continuous glucose monitor became available in 1999. Numerous clinical trials have documented the benefits of continuous glucose monitoring (CGM) in patients with type 1 diabetes mellitus (DM). However, the data supporting the use of CGM in type 2 DM patients are less substantial. This review article examines the clinical evidence for using CGM in patients with type 2 DM. An extensive literature search was performed to identify relevant studies for this review. Articles published in English from 2000 to May 2010 were identified through searches of PubMed and International Pharmaceutical Abstracts databases using the search terms type 2 DM and continuous glucose monitoring. Relevant references were examined for additional articles. The literature search revealed 27 original articles and reviews, 12 of which were included in this review. Five out of the 12 studies reviewed showed a decrease in glycosylated hemoglobin using CGM in patients with type 2 DM. The use of CGM in patients with type 2 DM can improve glycemic control, but other benefits include modification of diet and exercise, detection of unrecognized hypoglycemia, and identification of hyperglycemia excursions. © Copyright 2012, Mary Ann Liebert, Inc.. Source


Harris K.B.,Wingate University | McCarty D.J.,Wingate University
Therapeutic Advances in Endocrinology and Metabolism | Year: 2015

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first- and second-line diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin. Greater glycemic control was seen with liraglutide compared with the other GLP-1 treatment options; however, the two long-acting agents were superior to exenatide twice daily. All agents were well tolerated with most adverse events being mild or moderate in nature. The most common adverse event was transient nausea which typically resolved 4–8 weeks after treatment initiation. Long-acting agents had lower rates of nausea but an increased incidence of injection site reactions. Trials have suggested GLP-1 RAs may improve cardiovascular risk factors including blood pressure, lipid parameters and inflammatory markers. Future trials are needed to confirm the clinical outcomes of these agents. Overall, GLP-1 RAs will provide benefit for patients with T2DM intolerable to or not reaching glycemic goals with first-line agents, especially in patients in need of weight loss. © The Author(s), 2014. Source

Discover hidden collaborations